cervical adenocarcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3702
Name cervical adenocarcinoma
Definition A cervix carcinoma that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids
Xrefs
SNOMEDCT_US_2023_03_01:254887002
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer cervical cancer cervix carcinoma cervical adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 amp FGFR2 mut Zoligratinib cervical adenocarcinoma predicted - sensitive detail...
CD274 positive Camrelizumab cervical adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01101451 Phase III Cisplatin Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Completed USA 2
NCT02257528 Phase II Nivolumab Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting USA 0
NCT02348398 Phase II Pazopanib + Topotecan Phase II Study of Pazopanib and Topotecan in Cervical Cancer Withdrawn 0
NCT02466971 Phase III Cisplatin Cisplatin + Triapine Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Active, not recruiting USA | CAN 1
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Unknown status USA | ITA | GBR | ESP 2
NCT02595879 Phase I Cisplatin + Triapine Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer Active, not recruiting USA 0
NCT02834013 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02853604 Phase III ADXS11-001 Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV) Terminated USA | POL | ESP | CAN | BRA | ARG 8
NCT03108495 Phase II LN-145 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE 0
NCT03367871 Phase II Cisplatin + Paclitaxel + Pembrolizumab Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer Terminated USA 0
NCT03438396 Phase II Tisotumab vedotin-tftv A Trial of Tisotumab Vedotin in Cervical Cancer Completed USA | SWE | ITA | ESP | DNK | DEU | CZE | BEL 0
NCT03495882 Phase Ib/II Balstilimab + Zalifrelimab Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) Completed USA | POL | HUN | ESP | BRA | AUS 3
NCT03556839 Phase III Atezolizumab + Bevacizumab + Cisplatin + Paclitaxel Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) Active, not recruiting USA | SWE | NOR | ITA | FRA | ESP | DEU 1
NCT03612791 Phase II Cisplatin Atezolizumab + Cisplatin Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) Completed FRA 0
NCT03635567 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Completed USA | TUR | ITA | ISR | FRA | ESP | DEU | CAN | AUS | ARG 9
NCT03644342 Phase Ib/II Niraparib Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX) Terminated USA 0
NCT03738228 Phase I Atezolizumab + Cisplatin Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Completed USA 0
NCT03786081 Phase Ib/II Bevacizumab + Tisotumab vedotin-tftv Carboplatin + Tisotumab vedotin-tftv Pembrolizumab + Tisotumab vedotin-tftv Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer Active, not recruiting USA | TUR | NLD | ITA | IRL | GBR | ESP | DNK | CZE | BEL 0
NCT03830866 Phase III Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) Completed USA | POL | HUN | BRA 11
NCT03833479 Phase II Dostarlimab-gxly TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC) Active, not recruiting TUR | ESP 0
NCT03894215 Phase II Balstilimab Balstilimab + Zalifrelimab Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer Active, not recruiting USA | BRA 5
NCT04065269 Phase II Ceralasertib + Olaparib Ceralasertib ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) Active, not recruiting GBR | CAN 0
NCT04152499 Phase Ib/II Sacituzumab tirumotecan Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Active, not recruiting USA | TUR | CAN 3
NCT04205799 Phase II Cabozantinib Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure (CABOCOL-01) Completed FRA 0
NCT04221945 Phase III Cisplatin + Pembrolizumab Cisplatin Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11) Completed USA | TUR | SWE | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS 11
NCT04230954 Phase II Cabozantinib + Pembrolizumab Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer Terminated USA 0
NCT04238988 Phase II Carboplatin + Paclitaxel + Pembrolizumab Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (MITO CERV 3) Unknown status ITA 0
NCT04246489 Phase II Bintrafusp alfa Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer Completed USA | HUN | FRA | ESP | BRA | BEL | AUS | ARG 4
NCT04300647 Phase II Atezolizumab Atezolizumab + Tiragolumab A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) Completed USA | POL | ITA | GBR | FRA | ESP | CAN | BRA | AUS 8
NCT04381650 Phase Ib/II Pembrolizumab + Subasumstat A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Completed USA | POL | LVA | LTU | HRV | CHE | BRA 2
NCT04405349 Phase II Atezolizumab + VB10.16 Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer Completed POL | NOR | DEU | CZE | BGR | BEL 0
NCT04487587 Phase II Cediranib + Olaparib A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (COMICE) Active, not recruiting GBR 0
NCT04551950 Phase I Bevacizumab + Bintrafusp alfa + Carboplatin + Paclitaxel Bevacizumab + Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTRAPID 046) Completed USA | ESP 1
NCT04630353 Phase I HB-201 A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer Terminated USA 0
NCT04652076 Phase Ib/II Carboplatin + NP137 + Paclitaxel Trevatide + Pembrolizumab NP137 + Pembrolizumab Carboplatin + NP137 + Paclitaxel Carboplatin + Paclitaxel GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET) Active, not recruiting FRA 0
NCT04697628 Phase III Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) Completed USA | SWE | POL | NOR | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | ARG 7
NCT04943627 Phase III Topotecan Balstilimab Gemcitabine Irinotecan Pemetrexed Disodium Vinorelbine Balstilimab in Patients With Recurrent Cervical Cancer. Withdrawn USA 1
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Completed USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN 5
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Suspended USA 0
NCT05475171 Phase II MGD019 Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) Recruiting USA 0
NCT05492123 Phase II Ipilimumab + Nivolumab Cisplatin Cisplatin + Nivolumab Carboplatin + Nivolumab Carboplatin Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer Recruiting BRA 0
NCT05521997 Phase II Cisplatin + Telaglenastat Cisplatin Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer Not yet recruiting USA 0
NCT05527184 Phase I IMGN151 First in Human Study of IMGN151 in Recurrent Gynaecological Cancers Active, not recruiting USA | NLD | ITA | IRL | FRA | ESP | DEU | CAN | BEL | AUS 0
NCT05914116 Phase Ib/II DB-1311 + Enzalutamide Abiraterone + DB-1311 DB-1311 A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 2
NCT06079671 Phase III MEDI5752 Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical) Recruiting USA | TUR | POL | NOR | ITA | ESP | DNK | DEU | CAN | BRA 9
NCT06099418 Phase II VB10.16 Atezolizumab + VB10.16 Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. Withdrawn 0
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA | NOR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT06266338 Phase II Lenvatinib + Pembrolizumab Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) Recruiting USA 0
NCT06457997 Phase I PHN-010 A Study of PHN-010 in Patients With Advanced Solid Tumors Terminated USA 0
NCT06459180 Phase III Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Topotecan Sacituzumab tirumotecan A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) Recruiting USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 9
NCT06535607 Phase II MEDI5752 Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Fluorouracil + MEDI5752 Cisplatin + Fluorouracil + MEDI5752 Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (eVOLVE-02) Recruiting USA | BRA 4
NCT06543576 Phase Ib/II Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer Recruiting USA 0
NCT06598371 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors Recruiting USA 0
NCT06660654 Phase II Raludotatug deruxtecan A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) Recruiting USA | ITA | FRA | ESP | DNK | BEL 3
NCT06670911 Phase II Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Paclitaxel + Pembrolizumab Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. (ACCESS-I) Recruiting BRA 0
NCT06865677 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Terminated USA 0
NCT06925724 Phase II Ivonescimab A Study of Ivonescimab in People With Endometrial and Cervical Cancers Recruiting USA 0
NCT06953089 Phase II DB-1305 + DB-1311 BNT327 + DB-1311 DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 2
NCT07061977 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer Recruiting USA 0
NCT07070232 Phase Ib/II BNT327 + YL202 YL202 Itraconazole + YL202 A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors Recruiting USA | ITA | GBR | ESP | DEU | BEL | AUS 0
NCT07216703 Phase III Pembrolizumab + Sacituzumab tirumotecan Cisplatin + Paclitaxel + Pembrolizumab Bevacizumab + Pembrolizumab + Sacituzumab tirumotecan Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Pembrolizumab A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Recruiting USA | SWE | POL | ITA | ISR | HUN | ESP | CZE | CAN | BEL | ARG 3
NCT07368985 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer Not yet recruiting NLD 0